A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
Status:
Completed
Trial end date:
2019-06-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the
heart rate-corrected QT (QTc) interval. The study will last up to 41 days.